Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case study describes successful hair growth in a 59-year-old African-American female with central centrifugal cicatricial alopecia after switching to oral minoxidil treatment.

This research describes CG2001's promising safety profile and reduced systemic exposure as an alternative to finasteride, supporting its further development for androgenic alopecia treatment in future trials.

This study found that the novel alcohol-free topical foam CG2001, combining minoxidil and finasteride, was safe and well-tolerated in Chinese males with androgenetic alopecia, with significantly lower systemic exposure to finasteride compared to oral administration, potentially reducing sexual side effects.

In this phase I study, CG2001, a topical foam combining minoxidil and finasteride, was found to be safe and well-tolerated in Chinese males with androgenetic alopecia, showing significantly reduced systemic finasteride exposure compared to oral administration, potentially reducing related side effects.

This review reports that innovative topical treatments for dermatologic conditions like acne and atopic dermatitis show minimal systemic absorption, indicating improved safety and tolerability compared to traditional therapies.

This review discusses the criteria for evaluating treatments for androgenetic alopecia and emphasizes the importance of shared decision-making, noting no treatment currently meets all desired criteria of efficacy, safety, affordability, and ease of use.

In this case study, a patient with long-standing androgenic alopecia and lupus showed a satisfactory response to treatment with oral and topical minoxidil after suboptimal outcomes with previous treatments.

This bibliographic review highlights the importance of microneedling as a dermatological technique for treating androgenetic alopecia, emphasizing its potential benefits and the need for personalized treatment by skilled dermatologists.

This case report highlights that frontal fibrosing alopecia may be underrecognized in young women and notes that no single treatment regimen has been proven consistently effective for this condition.

This article introduces REVVup Hair Therapy as an alternative to surgery for early-stage hair loss but reports no new clinical findings.

This article involves an interview with dermatologist Rodney Sinclair and provides no new research findings.

In this study, five out of six patients treated with vemurafenib for metastatic melanoma experienced hair loss, which improved after topical steroid treatment.

This case report describes a 66-year-old man with frontal fibrosing alopecia, a rare lichen planopilaris variant, presenting with scarring alopecia at the hairline and extensive body hair loss.

Women pay more for the same 5% minoxidil foam than men, but prices for liquid solutions are similar.

Recent Phase III trials reported that once daily 5% minoxidil foam significantly increased hair count in women with female pattern hair loss and was shown to be as effective as twice daily 2% minoxidil solution.

In this case report, the authors describe complete recovery from acute diffuse and total alopecia linked to Borrelia infection after treatment with intravenous ceftriaxone and topical clobetasol foam.

This case series reports promising initial data on using microneedling with a dermaroller in trichotillomania patients, indicating potential efficacy in reducing compulsive hair-pulling behaviors and promoting hair regrowth.

In this case report, researchers observed that a 47-year-old woman developed pityriasis amiantacea after using topical minoxidil, suggesting a potential new etiology for this scalp condition.

This study found that compounded minoxidil solutions in a propylene glycol-free and alcohol-reduced foam remained stable for 180 days, meeting United States Pharmacopeia standards for strength, pH, and antimicrobial effectiveness.

This case report highlights that dermatoscopy and histopathological analysis were crucial for accurately diagnosing Lichen Planopilaris in two patients, leading to a correct diagnosis after initial misdiagnoses.

In this study, both 5% minoxidil foam and 5% minoxidil liquid solution effectively improved hair diameter and density in male patients with androgenetic alopecia over 12 weeks, with the foam formulation showing a slight advantage in patient satisfaction and hair density gain.

In this study, researchers found that a propylene glycol-free and alcohol-reduced topical foam containing minoxidil and finasteride remained chemically, physically, and microbially stable for 180 days when stored properly at room temperature in light-resistant containers.

This expert panel review developed consensus recommendations for managing androgenetic alopecia in Canadian adults, endorsing seven interventions like oral and topical medications and platelet-rich plasma.

This study highlights factors contributing to increasing seborrheic alopecia among teenagers, including hormonal, lifestyle, and psychological influences, and suggests integrated treatment strategies including medication, lifestyle adjustments, and psychological interventions.

Over 40% of postmenopausal women experience hair loss, with treatments aiming to stop further loss and possibly thicken hair.

Certain hairstyles can cause scalp diseases, smoking is linked to hair loss, 5% minoxidil foam is effective for hair loss treatment, and various factors influence wound healing and hair growth.

Minoxidil solution and foam both increase hair growth, but the solution works better than the foam.

This study reports that topical minoxidil 5% foam may effectively promote hair growth in congenital alopecia and hypotrichosis linked to desmoplakin mutations, as demonstrated by significant hair growth in an 8-year-old boy.

This study concluded that 5% minoxidil foam or solution applied twice daily is effective and safe for treating male androgenetic alopecia.

This case report details a 2-year-old boy who developed generalized hypertrichosis after using 5% minoxidil foam for alopecia areata, highlighting the importance of caution and proper administration instructions for young children.